0.72
+0(+0.00%)
Currency In USD
Address
6714 NW 16th Street
Gainesville, FL 32653
United States of America
Phone
386 418 8060
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
First IPO Date
May 03, 2000
| Name | Title | Pay | Year Born |
| N. Scott Fine | Chief Executive Officer & Director | 569,919 | 1957 |
| Jeffrey L. Tate | Chief Operating Officer, Chief Quality Officer & Director | 255,138 | 1958 |
| Joshua Fine | Chief Financial Officer & Secretary | 421,174 | 1982 |
| Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer | 430,402 | 1974 |
| Karen Mullen | Interim Chief Medical Officer | 0 | N/A |
| C. E Strattan | Founder & Director | 0 | 1946 |
| Lori McKenna | Global Head of Patient Advocacy | 0 | N/A |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
